title: Targeting metabotropic glutamate receptors as a new strategy against levodopa-induced dyskinesia in Parkinson's disease?
abstract: Levodopa-induced dyskinesias (LIDs) represent one major motor disability of Parkinson's disease (PD) therapy. Thus, research effort is still devoted to finding agents that may improve parkinsonism and concomitantly reduce or avoid dyskinesia. Rodent and nonhuman primate models provide useful tools to study the molecular and neuronal bases of LIDs. Among the various strategies investigated recently, the use of drugs targeting metabotropic glutamate receptors has received large attention. In particular, use of antagonists of the subtype 5 of metabotropic glutamate receptors revealed promising preclinical and clinical results.
authors.affiliation: Fondazione Santa Lucia, IRCCS, Rome, Italy.
authors.forename: Barbara
authors.initials: B
authors.lastname: Picconi
authors.forename: Paolo
authors.initials: P
authors.lastname: Calabresi
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000978:Antiparkinson Agents; D018094:Receptors, Metabotropic Glutamate; D007980:Levodopa
keywords: Parkinson's disease; dyskinesia; experimental animal models; levodopa therapy; mGluR5